Specification :

Ibutilide Fumrtate (Antiarrhythmic drugs cas: 122647-32-9 )
Apprance: Colorless transparent liquid
Pharmaco-toxicological :Ibutilide has extended the role of repolarization, is the first class b antiarrhythmic drug. In vitro results show that animal experiments can be extended Ibutilide rabbit ventricular effective refractory period, when the concentration of Ibutilide 9 ~ 10mol / L, the extended free guinea pig ventricular myocytes the time of the action potential. The experimental results show that the whole animal Ibutilide may terminate an animal model of canine atrial flutter and atrial fibrillation continued to extend the QT time. Ibutilide can reduce canine model of acute myocardial infarction and ventricular fibrillation incidence of ventricular tachycardia and ventricular fibrillation when lower defibrillation thresholds.
Pharmacokinetics:
Intravenous Ibutilide rapidly distributed in the extracellular fluid. Plasma volume of distribution of 6.6 ~ 13.4 min / L, 41% of the drug and the combination of plasma proteins. The majority of drug metabolism in the liver. In addition to a metabolite, the other seven had no active metabolites. Ibutilide t1 / 2 for 3 ~ 6 h. Metabolism of the drug from digoxin, ²-blockers, calcium channel antagonists affected. After oral administration of the drug with low bioavailability in general are intravenous drip.
Application: Ibutilide injection for the recent onset of atrial fibrillation or atrial flutter into sinus rhythm reversal of long-term atrial arrhythmia in patients sensitive Ibutilide. Ibutilide for the duration of more than 90 days in patients with heart disorders x Law efficacy has not been determined.